In photo, from left to right: Pelagio L. Emmanuel Jr., MD, Immediate Past President of the Philippine Society of Nephrology; Ricky Solitaria, Senior Product Manager at Boehringer Ingelheim (Philippines), Inc.; Seunghun Lee, Head of Marketing at Boehringer Ingelheim (Philippines), Inc.; and Ricardo A. Francisco Jr., MD, President of the Philippine Society of Nephrology. Boehringer Ingelheim (Philippines), Inc. received the prestigious Presidential Service Award from the Philippine Society of Nephrology in recognition of its commitment to empowering primary care physicians through the Kidney Disease Management for Primary Care Physicians (KDM4PCP) program, equipping them with the knowledge and tools to diagnose, manage, and treat chronic kidney disease (CKD) in the Philippines.
The Philippine Society of Nephrology (PSN) awarded Boehringer Ingelheim (Philippines), Inc. the prestigious Presidential Service Award during the Annual Convention Opening Ceremony on April 24, 2025, recognizing the company’s significant contribution to the Kidney Disease Management for Primary Care Physicians (KDM4PCP) program. This initiative provides primary care physicians with essential knowledge and the latest evidence-based guidelines to screen, assess risk, and manage chronic kidney disease (CKD) early. A key highlight was the two-day pre-convention scientific session held on April 22-23, 2025, at the Edsa Shangri-La Hotel. A KDM4PCP was also carried out in Zamboanga City as part of the recent World Kidney Day Celebration last March, focused on education and screening. This aims to further bridge healthcare gaps to underserved areas, empowering more healthcare professionals to deliver early and effective CKD care in communities that need it most. As CKD continues to impact millions of Filipinos, Boehringer Ingelheim remains committed to advancing healthcare through initiatives like KDM4PCP, focused on addressing the rising incidence of CKD and improving patient outcomes across the Philippines. To learn more about chronic kidney disease, visit ItStartsWithYou.com.ph.
Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma and Animal Health. Learn more at www.boehringer-ingelheim.com